143
Participants
Start Date
June 30, 2010
Primary Completion Date
November 30, 2010
Study Completion Date
November 30, 2010
insulin degludec
Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
insulin glargine
Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
Novo Nordisk Clinical Trial Call Center, Albany
Novo Nordisk Clinical Trial Call Center, Melrose Park
Novo Nordisk Clinical Trial Call Center, Charlotte
Novo Nordisk Clinical Trial Call Center, Kissimmee
Novo Nordisk Clinical Trial Call Center, Chattanooga
Novo Nordisk Clinical Trial Call Center, Kingsport
Novo Nordisk Clinical Trial Call Center, Chicago
Novo Nordisk Clinical Trial Call Center, Omaha
Novo Nordisk Clinical Trial Call Center, Metairie
Novo Nordisk Clinical Trial Call Center, Fort Worth
Novo Nordisk Clinical Trial Call Center, Austin
Novo Nordisk Clinical Trial Call Center, Phoenix
Novo Nordisk Clinical Trial Call Center, Goodyear
Novo Nordisk Clinical Trial Call Center, Chino
Novo Nordisk Clinical Trial Call Center, Anaheim
Novo Nordisk Clinical Trial Call Center, Fresno
Novo Nordisk Clinical Trial Call Center, Concord
Novo Nordisk Clinical Trial Call Center, Greenbrae
Novo Nordisk Clinical Trial Call Center, Olympia
Novo Nordisk Clinical Trial Call Center, Palm Springs
Novo Nordisk Clinical Trial Call Center, Metairie
Novo Nordisk Clinical Trial Call Center, Henderson
Novo Nordisk Clinical Trial Call Center, Dover
Novo Nordisk Clinical Trial Call Center, Nashua
Novo Nordisk Clinical Trial Call Center, Lawrenceville
Novo Nordisk Clinical Trial Call Center, Toms River
Novo Nordisk Clinical Trial Call Center, Pittsburgh
Lead Sponsor
Novo Nordisk A/S
INDUSTRY